Go Pro
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel Free KALA Stock Alerts

KALA BIO (KALA) Competitors

KALA BIO logo
$1.68 -0.10 (-5.62%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$1.76 +0.08 (+4.46%)
As of 07/2/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

KALA vs. SGMT, CNTN, CHRS, TARA, and VYGR

Should you buy KALA BIO stock or one of its competitors? MarketBeat compares KALA BIO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with KALA BIO include Sagimet Biosciences (SGMT), Hillstream Biopharma (CNTN), Coherus Oncology (CHRS), Protara Therapeutics (TARA), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.

How does KALA BIO compare to Sagimet Biosciences?

KALA BIO (NASDAQ:KALA) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

KALA BIO presently has a consensus price target of $1,018.75, suggesting a potential upside of 60,539.88%. Sagimet Biosciences has a consensus price target of $25.57, suggesting a potential upside of 236.02%. Given KALA BIO's higher probable upside, research analysts clearly believe KALA BIO is more favorable than Sagimet Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Sagimet Biosciences
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64

KALA BIO has higher earnings, but lower revenue than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KALA BION/AN/A-$26.98M-$96.14N/A
Sagimet Biosciences$2M123.97-$51.04M-$1.34N/A

In the previous week, Sagimet Biosciences had 1 more articles in the media than KALA BIO. MarketBeat recorded 1 mentions for Sagimet Biosciences and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.87 beat Sagimet Biosciences' score of 0.94 indicating that KALA BIO is being referred to more favorably in the media.

Company Overall Sentiment
KALA BIO Very Positive
Sagimet Biosciences Positive

Sagimet Biosciences' return on equity of -37.57% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
KALA BION/A -1,336.10% -94.85%
Sagimet Biosciences N/A -37.57%-35.52%

KALA BIO has a beta of -2.35, indicating that its stock price is 335% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.35, indicating that its stock price is 235% more volatile than the broader market.

Summary

Sagimet Biosciences beats KALA BIO on 10 of the 14 factors compared between the two stocks.

How does KALA BIO compare to Hillstream Biopharma?

KALA BIO (NASDAQ:KALA) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Hillstream Biopharma had 1 more articles in the media than KALA BIO. MarketBeat recorded 1 mentions for Hillstream Biopharma and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.87 beat Hillstream Biopharma's score of 0.00 indicating that KALA BIO is being referred to more favorably in the media.

Company Overall Sentiment
KALA BIO Very Positive
Hillstream Biopharma Neutral

KALA BIO currently has a consensus target price of $1,018.75, suggesting a potential upside of 60,539.88%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than Hillstream Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Hillstream Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Hillstream Biopharma's return on equity of -31.50% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
KALA BION/A -1,336.10% -94.85%
Hillstream Biopharma N/A -31.50%-24.72%

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

KALA BIO has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Hillstream Biopharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KALA BION/AN/A-$26.98M-$96.14N/A
Hillstream BiopharmaN/AN/A-$35.92M-$1.15N/A

Summary

KALA BIO beats Hillstream Biopharma on 7 of the 13 factors compared between the two stocks.

How does KALA BIO compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Coherus Oncology presently has a consensus price target of $8.67, suggesting a potential upside of 497.70%. KALA BIO has a consensus price target of $1,018.75, suggesting a potential upside of 60,539.88%. Given KALA BIO's higher possible upside, analysts clearly believe KALA BIO is more favorable than Coherus Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coherus Oncology
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Coherus Oncology's average media sentiment score of 1.89 beat KALA BIO's score of 1.87 indicating that Coherus Oncology is being referred to more favorably in the media.

Company Overall Sentiment
Coherus Oncology Very Positive
KALA BIO Very Positive

Coherus Oncology has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, meaning that its stock price is 335% less volatile than the broader market.

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Coherus Oncology has a net margin of 397.30% compared to KALA BIO's net margin of 0.00%. Coherus Oncology's return on equity of -198.90% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Coherus Oncology397.30% -198.90% -46.65%
KALA BIO N/A -1,336.10%-94.85%

Coherus Oncology has higher revenue and earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus Oncology$42.17M5.30$168.02M$1.670.87
KALA BION/AN/A-$26.98M-$96.14N/A

Summary

Coherus Oncology beats KALA BIO on 13 of the 14 factors compared between the two stocks.

How does KALA BIO compare to Protara Therapeutics?

KALA BIO (NASDAQ:KALA) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Protara Therapeutics had 3 more articles in the media than KALA BIO. MarketBeat recorded 3 mentions for Protara Therapeutics and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.87 beat Protara Therapeutics' score of 0.47 indicating that KALA BIO is being referred to more favorably in the media.

Company Overall Sentiment
KALA BIO Very Positive
Protara Therapeutics Neutral

KALA BIO currently has a consensus price target of $1,018.75, suggesting a potential upside of 60,539.88%. Protara Therapeutics has a consensus price target of $26.25, suggesting a potential upside of 546.55%. Given KALA BIO's higher probable upside, analysts clearly believe KALA BIO is more favorable than Protara Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Protara Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75

KALA BIO has a beta of -2.35, meaning that its share price is 335% less volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 2.2% of KALA BIO shares are held by company insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Protara Therapeutics' return on equity of -38.70% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
KALA BION/A -1,336.10% -94.85%
Protara Therapeutics N/A -38.70%-36.02%

Protara Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KALA BION/AN/A-$26.98M-$96.14N/A
Protara TherapeuticsN/AN/A-$57.44M-$1.34N/A

Summary

Protara Therapeutics beats KALA BIO on 9 of the 13 factors compared between the two stocks.

How does KALA BIO compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 2.2% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Voyager Therapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, meaning that its stock price is 335% less volatile than the broader market.

KALA BIO has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Voyager Therapeutics-319.61% -55.97% -43.12%
KALA BIO N/A -1,336.10%-94.85%

In the previous week, Voyager Therapeutics had 4 more articles in the media than KALA BIO. MarketBeat recorded 4 mentions for Voyager Therapeutics and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.87 beat Voyager Therapeutics' score of 0.79 indicating that KALA BIO is being referred to more favorably in the news media.

Company Overall Sentiment
Voyager Therapeutics Positive
KALA BIO Very Positive

Voyager Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 336.51%. KALA BIO has a consensus target price of $1,018.75, suggesting a potential upside of 60,539.88%. Given KALA BIO's higher probable upside, analysts plainly believe KALA BIO is more favorable than Voyager Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Voyager Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

KALA BIO has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$40.37M5.66-$119.72M-$1.97N/A
KALA BION/AN/A-$26.98M-$96.14N/A

Summary

Voyager Therapeutics beats KALA BIO on 11 of the 16 factors compared between the two stocks.

Get KALA BIO News Delivered to You Automatically

Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KALA vs. The Competition

Export
MetricKALA BIOMED IndustryMedical SectorNASDAQ Exchange
Market Cap$33.09M$3.65B$6.82B$12.56B
Dividend YieldN/A2.22%2.68%6.63%
P/E Ratio-0.0221.4327.9124.67
Price / SalesN/A324.18532.8396.34
Price / CashN/A143.2048.5958.15
Price / Book0.138.6610.896.45
Net Income-$26.98M$23.81M$3.57B$336.71M
7 Day Performance-33.33%3.47%2.24%1.37%
1 Month Performance-25.00%8.53%4.60%1.67%
1 Year Performance-99.36%62.64%33.47%24.05%

KALA BIO Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KALA
KALA BIO
3.1556 of 5 stars		$1.68
-5.6%		$1,018.75
+60,539.9%		-99.3%$33.09MN/AN/A30
SGMT
Sagimet Biosciences
3.232 of 5 stars		$6.93
-1.8%		$25.57
+269.0%		-6.2%$230.05M$2MN/A8
CNTN
Hillstream Biopharma
0.1256 of 5 stars		$2.66
-17.6%		N/AN/A$225.47MN/AN/A2
CHRS
Coherus Oncology
3.7066 of 5 stars		$1.52
+4.1%		$8.67
+470.2%		+82.4%$225.21M$42.17M0.91330
TARA
Protara Therapeutics
3.5012 of 5 stars		$4.03
+0.8%		$26.25
+551.4%		+46.0%$224.82MN/AN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KALA) was last updated on 7/3/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel